A share price of MaxCyte Inc [MXCT] is currently trading at $2.33, up 4.02%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MXCT shares have gain 9.91% over the last week, with a monthly amount glided 7.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MaxCyte Inc [NASDAQ: MXCT] stock has seen the most recent analyst activity on July 22, 2025, when Stephens initiated its Overweight rating and assigned the stock a price target of $6. Previously, Craig Hallum started tracking the stock with Buy rating on November 29, 2023, and set its price target to $7. William Blair started tracking the stock assigning a Outperform rating. Wedbush initiated its recommendation with a Outperform and recommended $36 as its price target on August 24, 2021. Stifel started tracking with a Buy rating for this stock on August 24, 2021, and assigned it a price target of $18. In a note dated August 24, 2021, Stephens initiated an Overweight rating and provided a target price of $19 on this stock.
MaxCyte Inc experienced fluctuations in its stock price throughout the past year between $2.00 and $5.20. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. MaxCyte Inc [NASDAQ: MXCT] shares were valued at $2.33 at the most recent close of the market. An investor can expect a potential return of 157.51% based on the average MXCT price forecast.
Analyzing the MXCT fundamentals
Trailing Twelve Months sales for MaxCyte Inc [NASDAQ:MXCT] were 37.68M which represents -8.39% decline. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -1.33%, Pretax Profit Margin comes in at -1.11%, and Net Profit Margin reading is -1.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.2 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.27 points at the first support level, and at 2.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.38, and for the 2nd resistance point, it is at 2.43.
Ratios To Look Out For
To put it in perspective, the Current Ratio for MaxCyte Inc [NASDAQ:MXCT] is 12.23. Also, the Quick Ratio is 11.58, while the Cash Ratio stands at 1.84. Considering the valuation of this stock, the price to sales ratio is 6.57, the price to book ratio is 1.24.
Transactions by insiders
Recent insider trading involved Hemrajani Rekha, Director, that happened on Jun 25 ’25 when 10684.0 shares were purchased. Chief Commercial Officer, Soleymannezhad Ali completed a deal on Mar 18 ’25 to sell 1211.0 shares. Meanwhile, GENERAL COUNSEL Sandoval David I. sold 353.0 shares on Mar 18 ’25.
